04/03/2009 11:36

CTL Writes Book Chapter on Validating Reference Samples for Use in Cell-Based Assays

In a new book on cell-based assays, CTL discusses key considerations in validating an ELISPOT assay.

Cellular Technology Limited has contributed a key chapter to the book, Validation of Cell-Based Assays in the GLP Setting: A Practical Guide. This text is one of the latest offerings by Research and Markets, a leading source for international market research and market data.

This book describes the development, optimization and validation of various cell-based assays, such as cytokine ELISPOT and ELISA assays, for which validation procedures have been developed. In addition, it discusses the validation of these assays for select targets using step-by-step instructions. Chapter 9 ("Validating reference samples for comparison in a regulated ELISPOT assay") was written by CTL personnel Magdalena Tary-Lehmann, Christina D. Hamm, and Paul V. Lehmann. In this chapter, they discuss the utility and performance of the ELISPOT method, as well as key considerations in validating such assays.

Validation of Cell-based Assays in the GLP Setting is an invaluable reference source for pharmaceutical companies and biotechnology firms that need to evaluate drug targets derived from genomics and proteomics. It is also a useful reference for companies that use cell-based technologies for biomarker discovery and development.

In addition, the potential of biomarkers to facilitate the development of effective and safe drugs is being recognized as an integral part of all phases of drug development, and cell-based technologies are a critical part of biomarker discovery and development.

 

For more information visit www.researchandmarkets.com/reports/c89231.

News archive

Featured products

CTL QC Sets™

CTL’s Reference Sample QC Sets™ offer outstanding inter-assay control. Use CTL's QC Sets™ not only for validation and protocol setup purposes, but also as internal controls for clinical trials...

CTL QC Sets™

Cryopreserved PBMC


Imagine the convenience of using a virtually unlimited number of PBMC aliquots, all from a single bleed.

Imagine having immediate access to a large library of precharacterized PBMC samples with established HLA types and antigen reactivities.

Imagine the assurance of knowing that your sample has tested negative for dangerous viruses.

CTL's frozen PBMC samples are the ideal solution. They're worry-free and hassle-free.

The thawed cells display over 95% viability thanks to CTL's revolutionary cryopreservation techniques. In addition, when tested for peptide or protein antigen-induced T cell recall responses in cytokine ELISPOT assays, the frequencies and per cell cytokine productivities of the thawed cells are easily comparable to those of fresh PBMC samples. Working with PBMCs has never been more convenient or more accurate!

CTL has built up a comprehensive library of donors characterized for:

  • HLA-type low/high resolution for three Class I and four Class II loci
  • Cytokine responses to 24 Class II individual CEF peptides, 32 Class I individual CEF-peptides, two Class I CEF peptide pools, one Class II CEF-peptide pool, and six protein-antigens
  • Demographics: Age, Gender, Ethnicity
  • Blood type (ABO and Rh Group/Type)
  • Vaccination status for Vaccinia, TB, and Hepatitis B

CTL PBMC samples are tested in the following screening systems and found to be negative:  

  • HIV 1/2 Antibody
  • HTLV I/II Antibody
  • Hepatitis B Surface Antigen
  • HCV Antibody
  • Hepatitis B Core Antibody
  • Serologic Test for Syphilis
  • NAT HIV/HCV
  • NAT WNV

Ready access to PBMC samples from the same donor and the same bleed can facilitate human immunological research and assay standardization within laboratories and between different laboratories.

Click for CTL's Cryopreserved PBMC Resource Section.

PBMC Products


Uncharacterized Cryopreserved PBMC

Cryopreserved PBMC with more than 90% post-thaw viability with performance comparable to fresh PBMC.

[see details]

Characterized Cryopreserved PBMC

Cryopreserved PBMC with more than 90% post-thaw viability with performance comparable to fresh PBMC. CTL's PBMC are characterized for immune reactivity to different recall antigens and peptides, HLA-typing, as well as gender, age, and ethnicity.

[see details]

CTL Anti-Aggregate™ Wash Supplement

Specifically formulated to prevent cell clumping and aggregation, thereby maximizing cell recovery. Also designed to increase metabolic activity after thawing.

[see details]

Displaying results 1 to 3 out of 3

Page 1